| Objective:By evaluating Muxianghuazhi Decoction’s therapeutic effects in the treatment of chronic atrophic gastritis accompanying qi stagnation and blood stasis,it provides a new idea and theoretical basis for the clinical treatment of this disease,confirms its clinical safety,so as to further promote its clinical application.Methods:From December 2021 to December 2022,in this study a total of 70 patients with chronic atrophic gastritis with Qi stagnation and blood stasis who qualified the inclusion criteria were enrolled at Wuhai Mongolian Hospital of Traditional Chinese Medicine.,and they were split up using a random number table into 35 patients for the treatment group,and35 patients for the control group.The treatment group was given oral treatment with Muxiang Huazhi Decoction supplemented with flavor,one dose a day,taken warm in the morning and evening after meals;the control group was given Mo Luo Dan treatment,9g,3times a day,orally,and the course of treatment was set for 24 weeks.The improvement of TCM symptoms,gastroscopy,and pathology before and after treatment were documented and compared after the course of treatment.The above data were analyzed and processed by statistical software SPSS23.0.Results :(1)Clinical symptoms: Comparison of epigastric pain,epigastric fullness,loss of appetite,frequent belching and acid regurgitation scores before and after treatment in the Muxiang Huazhou Decoction supplemented group was statistically significant(P < 0.01).The scores of dry mouth,bitter mouth,hypochondrial distention and pain were compared,all(P <0.05),which had statistical significance.The scores of epigastric pain,epigastric fullness,frequent belching,acid regurgitation,dry mouth and bitter mouth,and distension and pain in the side and ribs of Mo Luo Dan group before and after treatment were all compared,with statistical significance(P < 0.01).The score of loss of appetite was compared(P > 0.05),no statistical significance.After treatment session.,the epigastric pain,epigastric fullness,loss of appetite and belching frequency were compared,with statistical significance(P < 0.01).The scores of acid reflux,dry mouth and bitter mouth,hypochondriacal distension and pain were all compared,with no statistical significance(P > 0.05).Both groups were effective in improving the clinical symptoms of CAG patients,and the effect was more significant in the modified group of Muxiang Huazhi Decoction(P < 0.05);The total effective rate of Muxianghuazhi decoction group(94.29%)was also better than that of Mo Luo Dan group(80.00%)(P < 0.01).(2)Gastroscopic signs: both the Muxiang Huazhi Decoction group and Mo Luo Dan group were effective in improving the gastroscopic signs of CAG patients(P <0.05),the curative effect was more significant in the Muxiang Huazhi Decoction group(P <0.01);In terms of the total effective rate,the Muxiang Huazhi Decoction group(85.71%)was also better than the Mo Luo Dan group(62.86%)(P < 0.01).(3)Histopathology: Both groups had curative effects on improving gastric mucosa inflammation,reversing atrophy and intestinal metaplasia(P < 0.05),and the curative effect was more significant in the modified group of Muxianghuazhi Decoction(P < 0.01),there was no distinguished difference in the therapy effect of dysplasia between the two groups,because the number of cases of dysplasia in the two groups was small,mainly mild and no severe dysplasia,and the treatment result of dysplasia in the two groups was no statistical significance.Conclusions:Compared with Mo Luo Dan,the modified flavor of Muxiang Huazhou decoction can preferably improve the clinical symptoms of CAG patients,improve the gastroscopic manifestations and histopathological level of CAG patients,reduce the effects of gastric mucosal inflammation,atrophy and intestinal metaplasia,effectively prevent or reverse the progression of the disease,better improve the quality of life of patients,and at the same time have high safety.However,there is no conclusive evidence for the efficacy of dysplasia. |
PDF Full Text Request